Table 1.
Pretreatment characteristics by diagnosis (n=102)
| RS (%) | Relapsed/refractor y CLL (%) |
Total number of patients (%) |
|
|---|---|---|---|
| n=35 | n=67 | n=102 | |
| Age ≥ 60 yrs | 25 (71) | 41 (61) | 66 (65) |
| Zubrod PS = 2 | 9 (26) | 8 (12) | 17 (17) |
| Rai stage > II | 26 (74) | 48 (72) | 74 (73) |
| No. of prior therapies ≥ 3 | 19 (54) | 48 (72) | 67 (66) |
| B2-microglobulin ≥ 4 mg/L | 22 (30) | 51 (70) | 73 (72) |
| ALC > 30 × 109/L | 4 (13) | 26 (87) | 30 (29) |
| PLT < 100 × 109/L | 16 (46) | 41 (61) | 57 (56) |
| Albumin < 3.5 g/dL | 15 (43) | 6 (9) | 21 (21) |
| LDH > 1.5 × ULN | 11 (31) | 17 (27) | 28 (27) |
| Unmutated IgVH | 17 (85) | 45 (83) | 62 (61) |
| ZAP-70 positive* | 19 (73) | 47 (77) | 66 (65) |
| Fludarabine-refractory | 12 (34) | 32 (48) | 44 (43) |
| FISH(†) | |||
| 17p del | 6 (23) | 25 (44) | 31 (30) |
| 11q del | 3 (12) | 8 (14) | 11 (11) |
| Trisomy 12 | 5 (19) | 10 (18) | 15 (15) |
| del 13 | 5 (19) | 10 (18) | 15 (15) |
| Negative | 7 (27) | 4 (7) | 11 (11) |
Abbreviations: RS, Richter’s syndrome; CLL, chronic lymphocytic leukemia; PS, performance status; ULN, upper limit of normal; LDH, lactate dehydrogenase; ALC, absolute lymphocyte count; IgVH, immunoglobulin heavy-chain variable region gene rearrangement; FISH, fluorescence in situ hybridization; del, deletion.
*
By immunohistochemistry.36
†
No. of patients/total no. of patients with available data.